Compare Becton Dickinson and Co (BDX) vs BlackRock TCP Capital Corp (TCPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs BlackRock TCP Capital Corp — how do they compare? Becton Dickinson and Co trades at $154.29 (market cap $41.51B), while BlackRock TCP Capital Corp trades at $3.18 (market cap $265.55M). The key difference: Becton Dickinson and Co is far larger — about 156.3× BlackRock TCP Capital Corp's market cap, and BlackRock TCP Capital Corp pays the higher dividend (26.54%). Which is the better fit depends on your goals.
| BDX | TCPC | |
|---|---|---|
Market Cap | $41.51B | $265.55M |
Sector | Health | Financials |
52-Week High | $185.39 | $7.84 |
52-Week Low | $135.49 | $3.14 |
Enterprise Value | $57.97B | — |
Dividend Yield | 2.79% | 26.54% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
TCPC trades at $3.15, down 3.37% today, with a bearish technical signal and negative revenue trends. The company reported a net loss of $88.93M in 2025 despite a 112% net income margin, driven by negative revenue. Analyst consensus shows mixed sentiment with 31% buy ratings, while recent news includes a Zacks upgrade and upcoming Q2 earnings on August 6, 2026.
The outlook remains challenging with persistent negative revenue and profitability issues. Investment opportunities include the low P/B ratio of 0.47 and dividend yield, but risks include ongoing losses, shareholder litigation, and bearish technical indicators. The stock faces significant fundamental headwinds despite some analyst optimism.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About BlackRock TCP Capital Corp
BlackRock TCP Capital Corp is a finance company specializing in middle-market lending. It aims for high returns through income and capital appreciation while prioritizing principal protection. The company invests in debt securities and earns revenue from interest payments, fees, and some equity appreciation.
Read more on TCPC →
